About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01251874

Veliparib and Carboplatin in Treating Women With HER2-Negative MetastaticBreast Cancer

Study identifier: NCT01251874
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

  • Patients must have metastatic or locally advanced inoperable breast cancer that fulfills one of the following two criteria:
    • Triple-negative breast cancer
    • ER and/or PR positive, HER2 negative if their tumors have been shown to be deficient for the FA pathway
    • Her2 negative with a known germline deleterious BRCA1 or BRCA2 mutation
  • Patients with treated brain metastases and life expectancy of greater than 3 months allowed, however, patients with uncontrolled CNS metastasis are not eligible

Type of study:

Phase I

Treatment:

  • 21-day cycles with participants receiving carboplatin intravenously on day one and veliparib orally twice daily on either days 1-7 OR days 1-14

Study sites:

District of Columbia

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington, District of Columbia, 20007
Contact: Claudine Isaacs 202-444-3677 isaacsc@georgetown.edu        

Ohio
Columbus
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State
University Comprehensive Cancer Center
Contact: Bhuvaneswari Ramaswamy 614-293-6401 Bhuvaneswari.Ramaswamy@osumc.edu   

 

Page updated 06/10/13


Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org